HERALD EPOC1806 study explores trastuzumab deruxtecan in solid tumors with HER2 amplification by ctDNA
Stephen Liu shared a post on X:
“HERALD EPOC1806 study published in JCO explored trastuzumab deruxtecan (T-DXd, HER2 ADC: 5.4mg/kg q3w (every three weeks)) in solid tumors with HER2 amplification by ctDNA. In 13 different cancer types, RR (response rate) 56.5%, PFS (progression-free survival) 7 months, pneumonitis / ILD (interstitial lung disease ) in 26%. ctDNA clearance was favorable.”
Authors: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Odegaard, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Akihiro Sato, Takayuki Yoshino and Yoshiaki Nakamura.
Source: Stephen Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
